Bone Biologics (BBLG) Shares Outstanding (Weighted Average) (2010 - 2025)

Bone Biologics (BBLG) has 16 years of Shares Outstanding (Weighted Average) data on file, last reported at $1.2 million in Q4 2025.

• Shares Outstanding (Weighted Average) for Q4 2025 came in at $1.2 million, up 364.45% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.2 million (up 364.45% YoY), and the FY2025 annual result was $1.2 million, up 364.45% from the prior year.
• Shares Outstanding (Weighted Average) retreated to $1.2 million in Q4 2025 per BBLG's latest filing, from $1.8 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $10.4 million in Q1 2022 and troughed at $11800.0 in Q1 2021.
• A 5-year average of $1.5 million and a median of $345019.0 in 2022 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2021 and 2022: Shares Outstanding (Weighted Average) tumbled 99.84% in 2021, then jumped 87616.77% in 2022.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $4.5 million in 2021, then plunged by 98.95% to $47658.0 in 2022, then soared by 452.14% to $263137.0 in 2023, then slipped by 3.87% to $252960.0 in 2024, then soared by 364.45% to $1.2 million in 2025.
• Business Quant data shows BBLG's Shares Outstanding (Weighted Average) at $1.2 million in Q4 2025, $1.8 million in Q3 2025, and $544277.0 in Q2 2025.